12 High Dividend Stocks Picked By Billionaire Ray Dalio

9. Merck & Co., Inc. (NYSE:MRK)

Bridgewater Associates’ Stake Value as of Q4 2025: $32,653,862

Dividend Yield as of April 17: 2.91%

On April 17, Merck & Co., Inc. (NYSE:MRK) announced that the European Commission (EC) has approved ENFLONSIA (clesrovimab) to help prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during their first RSV season.

ENFLONSIA should not be used in infants who are hypersensitive to the active substance or any of its excipients. The treatment is a preventive, long-acting monoclonal antibody. It is designed to offer direct and fast protection that lasts up to five months, which typically covers a full RSV season. It also uses a non-weight-based dosing approach.

With this approval, ENFLONSIA can now be marketed across all 27 European Union member states, along with Iceland, Liechtenstein, and Norway. Availability will differ from country to country and will depend on factors such as reimbursement timelines. ENFLONSIA has already been approved in the United States, Canada, Switzerland, and several other markets for use in infants during their first RSV season. The company is continuing to seek approvals in additional countries.

Dr. Macaya Douoguih, vice president, Therapeutic Area Head, Global Clinical Development, Merck Research Laboratories, made the following statement:

“The European Commission approval of ENFLONSIA marks a significant milestone in our journey to enable broad access and help reduce the burden of RSV disease on infants around the world. We are proud to bring ENFLONSIA to infants in Europe and look forward to equipping families and health care providers with this important new preventive option to help address this widespread and potentially serious disease.”

Merck & Co., Inc. (NYSE:MRK) operates as a global healthcare company. It develops and delivers treatments through prescription medicines, including biologics, vaccines, and animal health products. Its pharmaceutical segment focuses on human health drugs and vaccines.